Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF.
BACKGROUND: Angiogenesis is a key hallmark of tumourigenesis and its inhibition is a proven strategy for the development of novel anti-cancer therapeutics. An important aspect of early angiogenesis is the co-ordinated migration and invasion of endothelial cells through the hypoxic tumour tissue. Cat...
Main Authors: | Claire Ward, Diana Kuehn, Roberta E Burden, Julie A Gormley, Thomas J Jaquin, Mihaela Gazdoiu, Donna Small, Roy Bicknell, James A Johnston, Christopher J Scott, Shane A Olwill |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2932732?pdf=render |
Similar Items
-
Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity
by: Kwok Hang Fai, et al.
Published: (2011-12-01) -
EDIL3 and VEGF Synergistically Affect Angiogenesis in Endothelial Cells
by: Niu X, et al.
Published: (2023-05-01) -
KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
by: Sawan Kumar Jha, et al.
Published: (2019-05-01) -
Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.
by: Li, J, et al.
Published: (2009) -
uPAR/cathepsin B overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR/cathepsin B down regulated meningioma.
by: Reshu Gupta, et al.
Published: (2011-02-01)